GE HealthCare Technologies Inc
For the period ended Sep 30, 2024. Filed Oct 30, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Oct 30, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Non-GAAP Financial Measures
The non-GAAP financial measures presented in this Quarterly Report on Form 10-Q are supplemental measures of our performance and our liquidity that we believe will help investors understand our financial condition, cash flows, and operating results, and assess our future prospects. When read in conjunction with our U.S. GAAP results, these non-GAAP financial measures provide a baseline for analyzing trends in our underlying businesses and can be used by management as one basis for making financial, operational, and planning decisions. Descriptions of the reported non-GAAP measures are included below.
We report Organic revenue and Organic revenue growth rate to provide management and investors with additional understanding and visibility into the underlying revenue trends of our established, ongoing operations, as well as provide insights into overall demand for our products and services. To calculate these measures, we exclude the effect of acquisitions, dispositions, and foreign currency rate fluctuations.
We report EBIT, Adjusted EBIT, Adjusted EBIT margin, Adjusted net income, and Adjusted earnings per share to provide management and investors with additional understanding of our business by highlighting the results from ongoing operations and the underlying profitability factors, on a normalized basis. To calculate these measures we exclude, and reflect in the detailed reconciliations below, the following adjustments as applicable: Interest and other financial charges - net, Net (income) loss attributable to noncontrolling interests, Non-operating benefit (income) costs, Benefit (provision) for income taxes and certain tax related adjustments, and certain non-recurring and/or non-cash items. We may from time to time consider excluding other non-recurring items to enhance comparability between periods. Adjusted EBIT margin is calculated by taking Adjusted EBIT divided by Total revenues for the same period.
We report Adjusted tax expense and Adjusted effective tax rate (“Adjusted ETR”) to provide investors with a better understanding of the normalized tax rate applicable to our business and provide more consistent comparability across periods. Adjusted tax expense excludes the income tax related to the pre-tax income adjustments included as part of Adjusted net income and certain income tax adjustments, such as adjustments to deferred tax assets or liabilities. We may from time to time consider excluding other non-recurring tax items to enhance comparability between periods. Adjusted ETR is Adjusted tax expense divided by income before income taxes less the pre-tax income adjustments referenced above.
We report Free cash flow to provide management and investors with an important measure of our ability to generate cash on a normalized basis and provide insight into our flexibility to allocate capital. Free cash flow is Cash from (used for) operating activities – continuing operations including cash flows related to the additions and dispositions of property, plant, and equipment (“PP&E”) and additions of internal-use software. Free cash flow does not represent residual cash flows available for discretionary expenditures, due to the fact that the measure does not deduct the capital required for debt repayments.
Management recognizes that these non-GAAP financial measures have limitations, including that they may be calculated differently by other companies or may be used under different circumstances or for different purposes. In order to compensate for the discussed limitations, management does not consider these measures in isolation from or as alternatives to the comparable financial measures determined in accordance with U.S. GAAP. The detailed reconciliations of each non-GAAP financial measure to the most directly comparable U.S. GAAP financial measure are provided below, and no single financial measure should be relied on to evaluate our business.
| Organic Revenue* | For the three months ended September 30 | For the nine months ended September 30 | ||||
|---|---|---|---|---|---|---|
| 2024 | 2023 | % change | 2024 | 2023 | % change | |
| Imaging revenues | $2,229 | $2,236 | —% | $6,462 | $6,552 | (1)% |
| Less: Acquisitions(1) | 16 | — | 29 | — | ||
| Less: Dispositions(2) | — | — | — | — | ||
| Less: Foreign currency exchange | (8) | — | (65) | — | ||
| Imaging Organic revenue* | $2,220 | $2,236 | (1)% | $6,497 | $6,552 | (1)% |
| AVS revenues | $1,216 | $1,214 | —% | $3,692 | $3,712 | (1)% |
| Less: Acquisitions(1) | — | — | — | — | ||
| Less: Dispositions(2) | — | — | — | — | ||
| Less: Foreign currency exchange | (2) | — | (22) | — | ||
| AVS Organic revenue* | $1,218 | $1,214 | —% | $3,713 | $3,712 | —% |
| PCS revenues | $779 | $764 | 2% | $2,298 | $2,315 | (1)% |
| Less: Acquisitions(1) | — | — | — | — | ||
| Less: Dispositions(2) | — | — | — | — | ||
| Less: Foreign currency exchange | — | — | (4) | — | ||
| PCS Organic revenue* | $779 | $764 | 2% | $2,302 | $2,315 | (1)% |
| PDx revenues | $625 | $589 | 6% | $1,862 | $1,715 | 9% |
| Less: Acquisitions(1) | — | — | — | — | ||
| Less: Dispositions(2) | — | — | — | — | ||
| Less: Foreign currency exchange | (5) | — | (13) | — | ||
| PDx Organic revenue* | $630 | $589 | 7% | $1,876 | $1,715 | 9% |
| Other revenues | $15 | $19 | (22)% | $39 | $52 | (25)% |
| Less: Acquisitions(1) | — | — | — | — | ||
| Less: Dispositions(2) | — | — | — | — | ||
| Less: Foreign currency exchange | — | — | — | — | ||
| Other Organic revenue* | $15 | $19 | (21)% | $39 | $52 | (25)% |
| Total revenues | $4,863 | $4,822 | 1% | $14,353 | $14,346 | —% |
| Less: Acquisitions(1) | 16 | — | 29 | — | ||
| Less: Dispositions(2) | — | — | — | — | ||
| Less: Foreign currency exchange | (15) | — | (104) | — | ||
| Organic revenue* | $4,863 | $4,822 | 1% | $14,427 | $14,346 | 1% |
| (1) | Represents revenues attributable to acquisitions from the date the Company completed the transaction through the end of four quarters following the transaction. |
| (2) | Represents revenues attributable to dispositions for the four quarters preceding the disposition date. |
| Adjusted EBIT* | For the three months ended September 30 | For the nine months ended September 30 | ||||
|---|---|---|---|---|---|---|
| 2024 | 2023 | % change | 2024 | 2023 | % change | |
| Net income attributable to GE HealthCare | $470 | $375 | 25% | $1,272 | $1,165 | 9% |
| Add: Interest and other financial charges – net | 130 | 138 | 383 | 411 | ||
| Add: Non-operating benefit (income) costs | (102) | (94) | (306) | (332) | ||
| Less: Benefit (provision) for income taxes | (168) | (250) | (435) | (550) | ||
| Less: Income (loss) from discontinued operations, net of taxes | — | (4) | — | (4) | ||
| Less: Net (income) loss attributable to noncontrolling interests | (19) | (7) | (40) | (33) | ||
| EBIT* | $685 | $680 | 1% | $1,825 | $1,831 | —% |
| Add: Restructuring costs(1) | 22 | 3 | 90 | 34 | ||
| Add: Acquisition and disposition-related charges (benefits)(2) | (4) | (14) | (7) | (15) | ||
| Add: Spin-Off and separation costs(3) | 56 | 45 | 182 | 175 | ||
| Add: (Gain) loss on business and asset dispositions(4) | 1 | — | — | — | ||
| Add: Amortization of acquisition-related intangible assets | 34 | 32 | 100 | 95 | ||
| Add: Investment revaluation (gain) loss(5) | 1 | (2) | 26 | (1) | ||
| Adjusted EBIT* | $795 | $744 | 7% | $2,217 | $2,119 | 5% |
| Net income margin | 9.7% | 7.8% | 190 bps | 8.9% | 8.1% | 70 bps |
| Adjusted EBIT margin* | 16.3% | 15.4% | 90 bps | 15.4% | 14.8% | 70 bps |
| (1) | Consists of severance, facility closures, and other charges associated with restructuring programs. |
| (2) | Consists of legal, consulting, and other transaction and integration fees, and adjustments to contingent consideration, as well as other purchase accounting related charges and other costs directly related to the transactions. |
| (3) | Costs incurred in the Spin-Off and separation from GE, including system implementations, audit and advisory fees, legal entity separation, Founders Grant equity awards, separation agreements with GE, and other one-time costs. |
| (4) | Consists of gains and losses resulting from the sale of assets and investments. |
| (5) | Primarily relates to valuation adjustments for equity investments. |
| Adjusted Net Income* | For the three months ended September 30 | For the nine months ended September 30 | ||||
|---|---|---|---|---|---|---|
| 2024 | 2023 | % change | 2024 | 2023 | % change | |
| Net income attributable to GE HealthCare | $470 | $375 | 25% | $1,272 | $1,165 | 9% |
| Add: Non-operating benefit (income) costs | (102) | (94) | (306) | (332) | ||
| Add: Restructuring costs(1) | 22 | 3 | 90 | 34 | ||
| Add: Acquisition and disposition-related charges (benefits)(2) | (4) | (14) | (7) | (15) | ||
| Add: Spin-Off and separation costs(3) | 56 | 45 | 182 | 175 | ||
| Add: (Gain) loss on business and asset dispositions(4) | 1 | — | — | — | ||
| Add: Amortization of acquisition-related intangible assets | 34 | 32 | 100 | 95 | ||
| Add: Investment revaluation (gain) loss(5) | 1 | (2) | 26 | (1) | ||
| Add: Tax effect of reconciling items(6) | (3) | (4) | (26) | (3) | ||
| Add: Spin-Off and other tax adjustments(7) | 46 | 106 | 60 | 136 | ||
| Less: Income (loss) from discontinued operations, net of taxes | — | (4) | — | (4) | ||
| Adjusted net income* | $521 | $451 | 16% | $1,393 | $1,258 | 11% |
| (1) | Consists of severance, facility closures, and other charges associated with restructuring programs. |
| (2) | Consists of legal, consulting, and other transaction and integration fees, and adjustments to contingent consideration, as well as other purchase accounting related charges and other costs directly related to the transactions. |
| (3) | Costs incurred in the Spin-Off and separation from GE, including system implementations, audit and advisory fees, legal entity separation, Founders Grant equity awards, separation agreements with GE, and other one-time costs. |
| (4) | Consists of gains and losses resulting from the sale of assets and investments. |
| (5) | Primarily relates to valuation adjustments for equity investments. |
| (6) | The tax effect of reconciling items is calculated using the statutory tax rate, taking into consideration the nature of the items and the relevant taxing jurisdiction. |
| (7) | Consists of certain income tax adjustments, including the accrual of a deferred tax liability on the prior period earnings of certain of the Company’s foreign subsidiaries for which the Company is no longer permanently reinvested, the impact of adjusting deferred tax assets and liabilities to stand-alone GE HealthCare tax rates, and the impact of tax legislation changes. As of the third quarter of 2024 this line additionally includes discrete tax impacts resulting from the Spin-Off and separation from GE previously reported under Tax effect of reconciling items. |
| Adjusted Earnings Per Share* · For the three months ended September 30 · For the nine months ended September 30 | ||||||||
|---|---|---|---|---|---|---|---|---|
| (In dollars, except shares outstanding presented in millions) · 2024 · 2023 · $ change · 2024 · 2023 · $ change | ||||||||
| Diluted earnings per share – continuing operations | $1.02 | $0.83 | $0.20 | $2.77 | $2.16 | $0.61 | ||
| Add: Deemed preferred stock dividend of redeemable noncontrolling interest | — | — | — | 0.40 | ||||
| Add: Non-operating benefit (income) costs | (0.22) | (0.21) | (0.67) | (0.73) | ||||
| Add: Restructuring costs(1) | 0.05 | 0.01 | 0.20 | 0.07 | ||||
| Add: Acquisition and disposition-related charges (benefits)(2) | (0.01) | (0.03) | (0.02) | (0.03) | ||||
| Add: Spin-Off and separation costs(3) | 0.12 | 0.10 | 0.40 | 0.38 | ||||
| Add: (Gain) loss on business and asset dispositions(4) | 0.00 | — | — | — | ||||
| Add: Amortization of acquisition-related intangible assets | 0.08 | 0.07 | 0.22 | 0.21 | ||||
| Add: Investment revaluation (gain) loss(5) | 0.00 | (0.00) | 0.06 | (0.00) | ||||
| Add: Tax effect of reconciling items(6) | (0.01) | (0.01) | (0.06) | (0.01) | ||||
| Add: Spin-Off and other tax adjustments(7) | 0.10 | 0.23 | 0.13 | 0.30 | ||||
| Adjusted earnings per share* | $1.14 | $0.99 | $0.15 | $3.04 | $2.75 | $0.29 | ||
| Diluted weighted-average shares outstanding | 459 | 458 | 459 | 458 | ||||
| (1) | Consists of severance, facility closures, and other charges associated with restructuring programs. |
| (2) | Consists of legal, consulting, and other transaction and integration fees, and adjustments to contingent consideration, as well as other purchase accounting related charges and other costs directly related to the transactions. |
| (3) | Costs incurred in the Spin-Off and separation from GE, including system implementations, audit and advisory fees, legal entity separation, Founders Grant equity awards, separation agreements with GE, and other one-time costs. |
| (4) | Consists of gains and losses resulting from the sale of assets and investments. |
| (5) | Primarily relates to valuation adjustments for equity investments. |
| (6) | The tax effect of reconciling items is calculated using the statutory tax rate, taking into consideration the nature of the items and the relevant taxing jurisdiction. |
| (7) | Consists of certain income tax adjustments, including the accrual of a deferred tax liability on the prior period earnings of certain of the Company’s foreign subsidiaries for which the Company is no longer permanently reinvested, the impact of adjusting deferred tax assets and liabilities to stand-alone GE HealthCare tax rates, and the impact of tax legislation changes. As of the third quarter of 2024 this line additionally includes discrete tax impacts resulting from the Spin-Off and separation from GE previously reported under Tax effect of reconciling items. |
| Adjusted Tax Expense* and Adjusted ETR* | For the three months ended September 30 | For the nine months ended September 30 | ||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Benefit (provision) for income taxes | $(168) | $(250) | $(435) | $(550) |
| Add: Tax effect of reconciling items(1) | (3) | (4) | (26) | (3) |
| Add: Spin-Off and other tax adjustments(2) | 46 | 106 | 60 | 136 |
| Adjusted tax expense* | $(124) | $(148) | $(401) | $(417) |
| Effective tax rate | 25.5% | 39.3% | 24.9% | 31.4% |
| Adjusted effective tax rate* | 18.7% | 24.4% | 21.9% | 24.4% |
| (1) | The tax effect of reconciling items is calculated using the statutory tax rate, taking into consideration the nature of the items and the relevant taxing jurisdiction. |
| (2) | Consists of certain income tax adjustments, including the accrual of a deferred tax liability on the prior period earnings of certain of the Company’s foreign subsidiaries for which the Company is no longer permanently reinvested, the impact of adjusting deferred tax assets and liabilities to stand-alone GE HealthCare tax rates, and the impact of tax legislation changes. As of the third quarter of 2024 this line additionally includes discrete tax impacts resulting from the Spin-Off and separation from GE previously reported under Tax effect of reconciling items. |
| Free Cash Flow* | For the nine months ended September 30 | ||
|---|---|---|---|
| 2024 | 2023 | % change | |
| Cash from (used for) operating activities – continuing operations | $1,042 | $1,051 | (1)% |
| Add: Additions to PP&E and internal-use software | (299) | (293) | |
| Add: Dispositions of PP&E | — | 1 | |
| Free cash flow* | $743 | $759 | (2)% |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.